SenesTech Inc Reports Q2 2025 Earnings: Revenue Hits $625,000, Evolve Product Line Drives Growth.

SenesTech Inc reported Q2 2025 earnings with revenue reaching $625,000, a 36% increase YoY, driven by a 94% YoY sales growth in Evolve Rodent Birth Control products. Despite this, the company faced a net loss of $1.6 million, including one-time legal expenses. The gross profit margin improved to 65.4%, up from 54.2% in Q2 2024. SenesTech Inc's balance sheet highlights a strong cash position with a current cash balance of $11.2 million, providing an operational runway through 2027.

SenesTech Inc. (NASDAQ: SNES) reported its second-quarter 2025 financial results, highlighting significant revenue growth and improved gross profit margins. The company's revenue reached $625,000, a 36% year-over-year (YoY) increase, driven primarily by a 94% YoY sales growth in Evolve Rodent Birth Control products [1].

Despite the revenue growth, SenesTech Inc. faced a net loss of $1.6 million for the quarter, including one-time legal expenses of $201,000 and non-cash operating lease expense of $38,000. Excluding these non-operational costs, the net loss would have been $1.4 million [1]. The gross profit margin improved to 65.4%, up from 54.2% in Q2 2024, indicating a stronger operational performance [1].

The company's balance sheet reflected a robust cash position, with a current cash balance of $11.2 million as of August 5, 2025. This cash balance provides an operating runway through 2027 and beyond, based on the most recent quarterly run rate [1].

Key highlights of SenesTech Inc.'s Q2 2025 performance include:

- Revenue Growth: The company's revenue increased by 36% YoY to $625,000, with Evolve Rodent Birth Control products contributing 83% of total revenue [1].
- Gross Profit Margin: The gross profit margin improved to 65.4%, a record for the company, compared to 54.2% in Q2 2024 [1].
- Operational Efficiency: Adjusted EBITDA loss improved to $1.4 million, compared to $1.5 million in the same quarter of the prior year and in Q1 2025 [1].
- Balance Sheet Strength: The current cash balance of $11.2 million ensures operational stability and growth potential [1].

SenesTech Inc. continues to expand its product offerings and distribution channels, with notable achievements including the launch of Evolve Rat and Evolve Mouse products, which are now the company's largest revenue drivers, and the growth of e-commerce revenue by 78% YoY [1]. The company also reported expanded municipal pilot deployments and strategic partnerships that have significantly accelerated adoption in retail locations across rural America [1].

The company's CEO, Joel Fruendt, stated, "Our results reflect the strength of our diverse multi-channel distribution strategy, with momentum across E-commerce, city and government deployments, brick-and-mortar retail, and international partnerships. As the pioneers in rodent birth control, we are directly reducing rodent populations and reshaping the multi-billion-dollar rodenticide industry with a scalable, science-driven solution delivering proven, sustainable results" [1].

SenesTech Inc. remains focused on achieving its breakeven goals and meeting its growth potential, with a strong cash position and a clear commitment to operational efficiency and profitability [1].

References:
[1] https://www.prnewswire.com/news-releases/senestech-reports-second-quarter-2025-financial-results-with-record-revenue-and-record-gross-profit-margins-302524618.html